Results 21 to 30 of about 1,341 (168)

Teprotumumab for Thyroid Eye Disease: Mechanism, Clinical Efficacy, and Current Challenges [PDF]

Antibodies
Thyroid eye disease (TED) is a complex autoimmune disorder characterized by orbital inflammation and tissue remodeling. Teprotumumab, a fully human monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), represents a significant ...
Yuan Zong, Shuang Qiu, Mingming Yang, Jing Zhang, Yaru Zou, Yuxin Jing, Kyoko Ohno-Matsui, Koju Kamoi   +7 more
doaj   +2 more sources

Preclinical pharmacology, pharmacokinetics, and pharmacodynamics of veligrotug, a full antagonist antibody to the IGF-1 receptor in development for thyroid eye disease [PDF]

mAbs
Clinical and preclinical studies have confirmed insulin-like growth factor-1 receptor (IGF-1R) antagonism can reduce the inflammation and proptosis occurring in thyroid eye disease (TED).
Rachel Kaplan, Yang Zhao, Jordan Tsai, Brent Dickinson, Tyler Swanson, Kelly Foster, Vahe Bedian   +6 more
doaj   +2 more sources

Teprotumumab versus intravenous methylprednisolone in thyroid eye disease: A systematic review

Oman Journal of Ophthalmology
Thyroid eye disease (TED), also known as thyroid-associated ophthalmopathy, is an autoimmune disorder caused due to a complex interplay between autoantigens including the thyroid-stimulating hormone receptor and the insulin-like growth factor-I receptor.
Faizan Mehmood, Syed Ali Raza Rizvi, Sarah Alam, Benazir Ansari   +3 more
doaj   +2 more sources

Orbital lymphocyte populations in three states of thyroid eye disease

American Journal of Ophthalmology Case Reports, 2023
Purpose: We report histopathologic orbital tissue analysis from three patients with thyroid eye disease (TED) – active, chronic, and post-teprotumumab to better characterize orbital cellular populations in these varying states of TED.
Shane M. Griffin, Rona Z. Silkiss
doaj   +1 more source

The Effect of Teprotumumab on Eyelid Position in Patients with Thyroid Eye Disease

Plastic and Reconstructive Surgery, Global Open, 2022
Summary:. Teprotumumab has been shown to improve proptosis and clinical activity scores (CAS) in patients with thyroid eye disease, but little has been published regarding its effects on eyelid retraction. The purpose of this work was to evaluate changes
Brittany A. Simmons, MD, Charlene Tran, BS, Chau M. Pham, MD, Erin M. Shriver, MD, FACS   +3 more
doaj   +1 more source

Intraocular pressure improvement in patients receiving teprotumumab for the treatment of thyroid eye disease: a case series

Journal of Medical Case Reports, 2022
Background Teprotumumab is a novel treatment that reduces inflammation and symptoms caused by thyroid eye disease. There are limited data on teprotumumab’s effect on intraocular pressure.
Matthew Chu, Jonathan Sung, Michael Song, Alice Song, Julia Song   +4 more
doaj   +1 more source

An Update on Medical Management of Thyroid Eye Disease with Insights on Teprotumumab

Delhi Journal of Ophthalmology, 2023
Thyroid eye disease (TED) is a debilitating autoimmune condition. It occurs most commonly with the hyperthyroid state but can also be seen in euthyroid and hypothyroid states.
Smriti Dabas, Nishi Meghna Satish, Sangeeta Abrol   +2 more
doaj   +1 more source

A comparison of proptosis reduction with teprotumumab versus surgical decompression based on fat-to-muscle ratio in thyroid eye disease [PDF]

, 2023
PurposeTo explore if orbital fat-to-muscle ratio (FMR) is predictive of whether surgical decompression or teprotumumab leads to greater proptosis reduction in thyroid eye disease (TED).MethodsA single-center retrospective cohort study comparing surgical ...
Kikkawa, Don O, Ediriwickrema, Lilangi S, Liu, Catherine Y, Topilow, Nicole J, Yoon, Jin Sook, Korn, Bobby S, Ting, Michelle AJ   +6 more
core   +1 more source

Facial and Eyelid Changes in Thyroid Eye Disease Are Reversed by Teprotumumab

Plastic and Reconstructive Surgery, Global Open, 2021
Background:. Thyroid eye disease (TED) causes orbital soft-tissue expansion. Recent studies have suggested that brow and temple changes may also occur. Teprotumumab, a monoclonal antibody to the insulin-like growth factor 1 receptor reduces soft-tissue ...
Shoaib Ugradar, MD, Jenna Braun, BS, Yao Wang, MD, Erin Zimmerman, AS, Raymond S. Douglas, MD, PhD   +4 more
doaj   +1 more source

Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma

Cancer Medicine, Volume 12, Issue 14, Page 15207-15216, July 2023., 2023
Abstract Background Ewing sarcoma (EWS) is an aggressive sarcoma with few treatment options for patients with relapsed disease. Cyclin‐dependent kinase 4 (CDK4) is a genomic vulnerability in EWS that is synergistic with IGF‐1R inhibition in preclinical studies.
David S. Shulman, Priscilla Merriam, Edwin Choy, Lillian M. Guenther, Kerri L. Cavanaugh, Pei‐Chi Kao, Andrew Posner, Ketki Bhushan, Grace Fairchild, Emma Barker, Kelly Klega, Kimberly Stegmaier, Brian D. Crompton, Wendy B. London, Steven G. DuBois   +14 more
wiley   +1 more source